Saxenda Alternatives: Other GLP-1 Options If Liraglutide Isn't Working

When daily liraglutide stops delivering enough weight loss, becomes hard to tolerate, or no longer fits a patient's routine, the usual question is: what are the Saxenda alternatives? Interest in a Saxenda alternative has grown as newer GLP-1 and dual-incretin medicines have arrived, and the choice is no longer between two drugs only.

Our earlier guide, Comparing Wegovy and Saxenda: Which Weight Loss Medication Is Right for You, looks at those two medicines side by side. This article takes a wider view: when clinicians typically decide liraglutide is not working, how weekly semaglutide, tirzepatide and oral semaglutide compare, and when non-GLP-1 care is more appropriate. It is not medical advice. Any change in therapy must be decided with a licensed prescriber.

When Is Saxenda "Not Working"?

Saxenda (liraglutide 3 mg) is a once-daily GLP-1 receptor agonist used, with diet and activity, for chronic weight management. "Not working" is a clinical judgement, but official labels give clear review points:

• Inadequate weight loss. The US prescribing information says adults should be reviewed 16 weeks after starting Saxenda and the medicine discontinued if they have not lost at least 4% of baseline body weight. In the European Union, the European Medicines Agency advises stopping treatment after 12 weeks on the 3.0 mg daily dose if an adult has not lost at least 5% of initial body weight.

• Poor tolerability. The US label also says to discontinue Saxenda if the patient cannot tolerate the 3 mg dose. Gastrointestinal effects — nausea, vomiting, diarrhoea and constipation — are the most common Saxenda side effects and the usual reason a maintenance dose cannot be held.

• Adherence or preference. A daily injection is a real burden for some people. A weekly injection or a tablet may be a better fit even when liraglutide is otherwise tolerated.

• A later plateau. Early weight loss followed by a stall does not automatically mean a switch, but it often prompts a review of dose, diet, activity and whether another medicine would help.

A plateau or a slow start is not, on its own, a reason to combine two GLP-1 medicines; labels for these products advise against using them together.

Saxenda Alternatives at a Glance

The comparison below summarises typical trial results, not what any one person will lose. All of these medicines are used with diet and activity, and indication, dose and availability vary by country.

Ozempic contains the same active ingredient as Wegovy injection (semaglutide) but is approved for type 2 diabetes, not as a weight-management substitute for Saxenda. Victoza is liraglutide at a lower diabetes dose, so it is not a step up. Compounded or unregulated "semaglutide" products are not the same as authorised medicines and should be avoided.

Weekly Semaglutide (Wegovy): The Most Common Next Step

For many patients who need a more effective GLP-1 option, once-weekly semaglutide 2.4 mg is the first alternative a clinician considers. In STEP 8, adults without diabetes lost a mean 15.8% of body weight on semaglutide 2.4 mg weekly versus 6.4% on liraglutide 3.0 mg daily over 68 weeks, and 70.9% versus 25.6% reached at least 10% weight loss (Rubino et al., JAMA 2022). Gastrointestinal side effects were similarly common in both groups, so a switch is not a guarantee of better tolerability. For timing and titration, see our guide to switching from Saxenda to Wegovy. For background on the molecule, read Understanding Semaglutide Injection and Its Uses.

Tirzepatide (Zepbound): A Dual GIP and GLP-1 Option

Tirzepatide is a dual GIP and GLP-1 receptor agonist, given once weekly. In the United States it is approved as Zepbound for chronic weight management and, separately, as Mounjaro for type 2 diabetes. In the SURMOUNT-1 trial in adults with obesity or overweight without diabetes, mean weight loss at 72 weeks was 15.0% with 5 mg, 19.5% with 10 mg and 20.9% with 15 mg, compared with 3.1% with placebo (Jastreboff et al., New England Journal of Medicine 2022).

Those figures come from a placebo-controlled trial, not a head-to-head study against Saxenda, so they should not be read as a direct "versus liraglutide" result. They do help explain why clinicians consider tirzepatide when a larger effect is needed or a GLP-1 agonist has already been used. Zepbound must not be combined with another GLP-1 receptor agonist. It carries the same class boxed warning about thyroid C-cell tumors in rodents and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Starting dose, escalation and any gap after liraglutide are decisions for the prescriber.

Oral Semaglutide If Injections Are the Barrier

If the problem is the injection itself rather than the medicine class, an oral option may be relevant. In December 2025 the US Food and Drug Administration approved a once-daily Wegovy tablet (semaglutide 25 mg) for chronic weight management in adults, based on the OASIS 4 trial. At 64 weeks, mean weight change was about 13.6% with oral semaglutide 25 mg versus about 2.2% with placebo (Wharton et al., New England Journal of Medicine 2025). That is a different product and a much higher dose than Rybelsus, the oral semaglutide tablet approved for type 2 diabetes, so the two are not interchangeable.

Availability is still uneven. The tablet was first launched in the United States, and approval elsewhere can lag. Patients who want to avoid injections should ask what is authorised locally, rather than assuming a diabetes tablet can be used as a Saxenda substitute.

If Side Effects Are the Reason You Want an Alternative

Saxenda side effects are a common reason for looking at alternatives, so it helps to separate expected effects from warning signs. Nausea and other gastrointestinal symptoms are very common with liraglutide and with the newer agents in this class. Smaller meals, stopping when full, and slower dose escalation often help. If a switch is being considered because of gastrointestinal intolerance, many clinicians wait until symptoms settle, then start the next medicine at its lowest dose.

Seek urgent medical care for severe, persistent abdominal pain (a possible sign of pancreatitis), a serious allergic reaction, or signs of gallbladder or kidney problems. The GLP-1 and dual-incretin options discussed here share important contraindications, including a personal or family history of medullary thyroid carcinoma or MEN 2. A medicine in the same class will not automatically solve a class-related side effect.

Non-GLP-1 Options and the Rest of the Care Plan

Not every patient who stops Saxenda should move to another incretin medicine. Other authorised weight-management medicines — such as orlistat, phentermine-topiramate or naltrexone-bupropion, depending on the country — may be appropriate when injections or GLP-1 effects are not suitable. Diet and activity support remains the foundation, with or without medication. For some people with a higher BMI or weight-related complications, metabolic or bariatric surgery is the more effective next step.

Whatever is chosen, the medicine works alongside, not instead of, nutrition, activity and follow-up. Unrealistic early expectations, skipped titration and unregulated online products are common reasons a second attempt also fails.

What This Means for Clinics and Distributors

As more patients move from daily liraglutide to weekly or oral alternatives, aesthetic and wellness clinics are seeing related demand for body contouring and volume restoration after substantial weight loss. Prescription GLP-1 care should stay under medical supervision, with evidence-based adjuncts rather than unregulated lookalikes. AOMA's range of weight loss and fat-dissolving injections is one example of clinic-side products that sit alongside, not in place of, prescription incretin therapy.

Brands and distributors exploring a private-label weight-management line can read Exploring OEM Weight Loss Injections: A Strategic Opportunity for Health and Wellness Businesses. AOMA is a Hangzhou-based OEM/ODM manufacturer of medical-aesthetic and weight-loss injectables, with CE, ISO 13485, GMP and FDA certificates. MOQ starts from 200 units, stock orders ship within 24 hours, and OEM lead time is 2–3 weeks after artwork, formula and packaging are confirmed.

FAQ

What is the best Saxenda alternative?

There is no single best option. Weekly semaglutide has the most direct head-to-head evidence against liraglutide. Tirzepatide has produced larger average losses in placebo-controlled trials. An oral tablet may suit someone who wants to avoid injections. The right choice depends on medical history, tolerability, local approval and what the patient can stick with — a decision for a licensed prescriber.

Can I switch from Saxenda to Wegovy or Zepbound on my own?

No. These are prescription-only medicines. Doses are not interchangeable, the drugs should not be taken together, and titration, diabetes medicines and side effects all need clinical review.

Is Ozempic a Saxenda alternative?

Ozempic is semaglutide approved for type 2 diabetes, not a weight-management indication. Wegovy uses the same molecule at a dose and schedule studied for chronic weight management. Using a diabetes product as a Saxenda substitute, if considered at all, belongs under a clinician's care and local rules.

What if Saxenda side effects are the problem?

Gastrointestinal effects are common across this class, so a switch does not guarantee they will disappear. If intolerance is the reason for changing, clinicians often wait until symptoms settle, then start the next medicine at its lowest dose. Urgent symptoms such as severe abdominal pain need medical care, not a do-it-yourself change.

Do I need a washout period after stopping Saxenda?

It depends on why you are stopping and which medicine comes next. For a planned switch to weekly semaglutide, published guidance often allows the new medicine to start the day after the last daily dose. If the change is because of side effects, a short wait is more common. Your prescriber should decide.

Medical Disclaimer

This article is for general education and for healthcare and industry professionals. It is not medical advice. Saxenda, Wegovy, Ozempic, Rybelsus, Victoza, Zepbound and Mounjaro are prescription-only medicines. Any change in therapy must be decided by a licensed prescriber according to the local label. AOMA does not manufacture or sell these products. Saxenda, Wegovy, Ozempic, Rybelsus and Victoza are trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are trademarks of Eli Lilly and Company.

References

1. SAXENDA (liraglutide) injection, US Prescribing Information. Novo Nordisk. DailyMed, updated February 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143

2. European Medicines Agency. Saxenda (liraglutide) EPAR. https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda

3. Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138-150. PMID: 35015037.

4. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024.

5. Wharton S, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). N Engl J Med. 2025. doi:10.1056/NEJMoa2500969. PMID: 40934115.